Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation

Transplantation Proceedings
R WackeW Schareck

Abstract

The optimal effect of therapy with cyclosporine (CsA) seeks to minimize undesirable side effects while maximizing immunosuppression. This balance, depends on CsA exposure, which may be characterized by the area under the concentration-time-curve (AUC). Therefore, we tested the pharmacokinetic profile of microemulsion CsA as a superior approach to guide clinical immunosuppression after de novo simultaneous pancreas-kidney transplantations. We examined 10 consecutive pancreas-kidney recipients with type 1 diabetes and end-stage renal disease. All patients were treated with a regimen consisting of CsA, mycophenolate mofetil (MMF), and prednisone. Full (9-point) pharmacokinetic studies (C0, C1, C2, C3, C4, C6, C8, C10, C12) were performed on week 1 and during week 3 to examine CsA pharmacokinetic profiles. Mean AUC0-12 of 4431 +/- 2400 microg x h/L at week 1 remained stable at week 3 (5119 +/- 1190 microg x h/L). The C6 sampling time displayed the best correlation with AUC0-12 (r2 = 0.881), followed by C3 (r2 = 0.758). Our preliminary data after simultaneous pancreas-kidney transplantation support the hypothesis that C3 or C6 sampling is a more accurate predictor of the AUC0-12 than C0. The combination of two samplings, namely C3 +...Continue Reading

References

May 16, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Serge C L M CremersJohan W de Fijter
Oct 28, 2003·Transplantation·Karsten MidtvedtTorbjoern Leivestad
Dec 13, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Gunilla EineckeKlemens Budde

❮ Previous
Next ❯

Citations

Oct 28, 2009·Experimental Diabetes Research·Khalid M Alkharfy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
Wichian JulasareekulTada Seublinvong
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
Vartan MardigyanMarcelo Cantarovich
Transplantation Proceedings
Jacques MalaiseEuroSPK Study Group
Therapeutic Drug Monitoring
Lutz T WeberMembers of the German Study Group on Pediatric Renal Transplantion
© 2022 Meta ULC. All rights reserved